David Kerstein - Mar 1, 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
Chief Medical Officer
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Stock symbol
THRX
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
3/2/2023, 06:01 AM
Previous filing
Feb 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Restricted Stock Units Award $0 +17.5K $0.00 17.5K Mar 1, 2023 Common Stock 17.5K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2 The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date.